|
|
v | |
Preface |
|
ix | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 | (4) |
|
Structural and biochemical properties |
|
|
5 | (1) |
|
Localization of somatostatin binding sites in the central nervous system |
|
|
6 | (4) |
|
Localization of somatostatin receptor subtypes |
|
|
10 | (23) |
|
|
10 | (1) |
|
|
10 | (4) |
|
|
14 | (1) |
|
|
15 | (1) |
|
|
15 | (2) |
|
|
17 | (10) |
|
|
27 | (1) |
|
|
27 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
28 | (1) |
|
|
29 | (1) |
|
|
30 | (1) |
|
|
30 | (1) |
|
|
30 | (3) |
|
Somatostatin receptors in brain disorders |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
33 | (1) |
|
|
34 | (1) |
|
|
34 | (1) |
|
|
35 | (1) |
|
|
36 | (9) |
|
Brain PACAP/VIP Receptors: Regional Distribution, Functional Properties and Physiological Relevance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 | (1) |
|
Biosynthesis of VIP and PACAP |
|
|
45 | (1) |
|
VIP and PACAP binding sites |
|
|
45 | (1) |
|
Distribution of VIP and PACAP receptors |
|
|
46 | (6) |
|
Autoradiographic distribution of VIP binding sites in rodent brain |
|
|
46 | (5) |
|
Distribution of PACAP binding sites in rat brain |
|
|
51 | (1) |
|
Comparison between the distribution of VIP and PACAP binding sites |
|
|
51 | (1) |
|
Molecular cloning and pharmacological characterization of VIP/PACAP receptors |
|
|
52 | (6) |
|
VPAC1 and VPAC2: two genes, two receptors |
|
|
52 | (1) |
|
PAC1: one gene, seven receptors (at least) |
|
|
53 | (1) |
|
|
54 | (2) |
|
Distribution of VPAC1 and VPAC2 receptors in rat brain |
|
|
56 | (1) |
|
Distribution of PAC1 receptor mRNA |
|
|
57 | (1) |
|
|
58 | (2) |
|
VPAC1, VPAC2: two receptors, one effector |
|
|
58 | (1) |
|
PAC1: seven receptors, two effectors |
|
|
58 | (1) |
|
Agonist-directed PAC1 receptor trafficking of PLC stimulation |
|
|
59 | (1) |
|
Additional PAC1 receptor signal transduction |
|
|
60 | (1) |
|
Trophic actions of VIP and PACAP |
|
|
60 | (2) |
|
Neurotrophic actions elicited by VIP |
|
|
60 | (1) |
|
Stimulation of early embryonic growth by VIP |
|
|
61 | (1) |
|
VIP protects against excitotoxic cell death |
|
|
61 | (1) |
|
Neurotrophic and anti-apoptotic properties of PACAP |
|
|
62 | (1) |
|
Involvement of VIP/PACAP in circadian rhythms and sleep |
|
|
62 | (1) |
|
Involvement of VIP/PACAP in circadian rhythms |
|
|
62 | (1) |
|
VIP and PACAP are involved in sleep regulation |
|
|
63 | (1) |
|
Regulation of brain energy metabolism by VIP |
|
|
63 | (2) |
|
Regulation by VIP of genes controlling glycogen metabolism |
|
|
64 | (1) |
|
|
64 | (1) |
|
The C/EBP family of transcription factors |
|
|
64 | (1) |
|
Modulation by VIP and PACAP of glutamate-mediated signalling in the cerebral cortex |
|
|
65 | (5) |
|
VIP and PACAP potentiate the glutamate-evoked release of arachidonic acid |
|
|
65 | (2) |
|
VIP and PACAP potentiate the actions of glutamate on BDNF and c-fos expression |
|
|
67 | (3) |
|
|
70 | (2) |
|
|
72 | (1) |
|
|
73 | (6) |
|
Localization of Angiotensin Receptors in the Nervous System |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
79 | (3) |
|
Renin--angiotensin system |
|
|
79 | (1) |
|
Renin--angiotensin system in the brain |
|
|
79 | (1) |
|
Actions of angiotensin in the brain |
|
|
79 | (1) |
|
Production of angiotensin in the brain |
|
|
79 | (2) |
|
|
81 | (1) |
|
|
81 | (1) |
|
|
81 | (1) |
|
Other receptors of the angiotensin system |
|
|
82 | (1) |
|
|
82 | (1) |
|
Localization of AT1 and AT2 receptors |
|
|
82 | (25) |
|
Localization by autoradiography or hybridization histochemistry |
|
|
83 | (4) |
|
Distribution of AT1 and AT2 receptors in the rat brain |
|
|
87 | (1) |
|
|
88 | (5) |
|
|
93 | (3) |
|
|
96 | (1) |
|
|
96 | (1) |
|
Amygdala and bed nucleus of the stria terminalis |
|
|
97 | (1) |
|
|
97 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
|
98 | (1) |
|
Brainstem nuclei associated with cardiovascular, respiratory and other autonomic functions |
|
|
99 | (1) |
|
|
99 | (1) |
|
|
99 | (1) |
|
The pre-cerebellar and cerebellar nuclei |
|
|
100 | (1) |
|
|
100 | (1) |
|
Immunohistochemical detection of AT1 receptors |
|
|
100 | (1) |
|
Distribution of AT1 receptor immunoreactivity in the rat brain |
|
|
100 | (5) |
|
The distribution of AT1 and AT2 receptors in other species |
|
|
105 | (1) |
|
|
105 | (1) |
|
Ascending dopaminergic neurons in the substantia nigra |
|
|
105 | (2) |
|
|
107 | (1) |
|
Overview of AT1 receptor functions in selected brain regions |
|
|
107 | (6) |
|
|
107 | (1) |
|
Immediate early gene expression |
|
|
107 | (2) |
|
|
109 | (2) |
|
|
111 | (1) |
|
The hypothalamic paraventricular nucleus |
|
|
111 | (1) |
|
|
111 | (1) |
|
|
111 | (1) |
|
|
112 | (1) |
|
|
112 | (1) |
|
Nucleus of the solitary tract |
|
|
112 | (1) |
|
Dorsal motor nucleus of vagus |
|
|
112 | (1) |
|
The ventrolateral medulla |
|
|
113 | (1) |
|
|
113 | (1) |
|
|
114 | (4) |
|
|
118 | (1) |
|
|
118 | (7) |
|
Brain Endothelin and Natriuretic Peptide Receptors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Why endothelin and natriuretic receptors? |
|
|
125 | (1) |
|
Brain endothelin receptors |
|
|
125 | (8) |
|
|
125 | (1) |
|
Distribution of endothelins |
|
|
125 | (1) |
|
|
126 | (1) |
|
Quantification of endothelin receptors and their subtypes |
|
|
126 | (1) |
|
How many receptor subtypes? |
|
|
126 | (1) |
|
Distribution of ET receptors |
|
|
127 | (1) |
|
|
127 | (1) |
|
Immunocytochemical studies |
|
|
127 | (3) |
|
In situ hybridization studies |
|
|
130 | (2) |
|
Signal transduction mechanisms |
|
|
132 | (1) |
|
Functions of endothelin receptors in the brain |
|
|
132 | (1) |
|
Brain natriuretic peptide receptors |
|
|
133 | (20) |
|
|
133 | (2) |
|
Distribution of natriuretic peptides in the brain |
|
|
135 | (1) |
|
Natriuretic peptide receptors |
|
|
136 | (1) |
|
Quantification of natriuretic peptide receptors and their subtypes |
|
|
137 | (1) |
|
How many receptor subtypes? |
|
|
137 | (1) |
|
Distribution of natriuretic peptide receptors |
|
|
138 | (1) |
|
|
138 | (3) |
|
In situ hybridization studies |
|
|
141 | (5) |
|
Comparative distribution of ANP immunoreactivity and ANP receptors |
|
|
146 | (1) |
|
Signal transduction mechanisms |
|
|
147 | (1) |
|
Functions of natriuretic peptide receptors in the brain |
|
|
147 | (5) |
|
|
152 | (1) |
|
Interactions between natriuretic peptides, endothelin and angiotensin II |
|
|
153 | (1) |
|
|
153 | (10) |
|
Neuropeptide FF Receptors |
|
|
|
|
|
|
|
|
|
|
|
|
163 | (1) |
|
Pharmacological activities of neuropeptide FF |
|
|
163 | (2) |
|
Neuropeptide FF as a neurotransmitter |
|
|
165 | (1) |
|
Release of neuropeptide FF |
|
|
165 | (1) |
|
Distribution of neuropeptide FF |
|
|
165 | (1) |
|
Distribution of neuropeptide FF-immunoreactivity in rat brain |
|
|
165 | (1) |
|
Neuropeptide FF in rat spinal cord |
|
|
166 | (1) |
|
Neuropeptide FF receptors |
|
|
166 | (18) |
|
Methodological considerations |
|
|
166 | (1) |
|
Biochemical characterization of [125I]1DMe on spinal cord sections |
|
|
167 | (1) |
|
Pharmacological specificity of [125I]1DMe binding |
|
|
168 | (1) |
|
Brain neuropeptide FF receptors, autoradiographic distribution |
|
|
168 | (1) |
|
|
169 | (1) |
|
|
169 | (1) |
|
|
169 | (6) |
|
|
175 | (5) |
|
|
180 | (2) |
|
|
182 | (2) |
|
Brain neuropeptide FF receptors in other species |
|
|
184 | (2) |
|
Neuropeptide FF receptors in rodents |
|
|
184 | (1) |
|
Neuropeptide FF receptors in lagomorphs |
|
|
184 | (2) |
|
Neuropeptide FF receptors in man |
|
|
186 | (1) |
|
|
186 | (2) |
|
|
188 | (2) |
|
|
190 | (1) |
|
|
190 | (5) |
|
Neurokinin Receptors in the CNS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
195 | (1) |
|
Discovery of the tachykinins |
|
|
195 | (1) |
|
Distribution of tachykinin-like immunoreactivity |
|
|
196 | (1) |
|
Physiological functions of tachykinins |
|
|
197 | (1) |
|
|
198 | (31) |
|
|
198 | (2) |
|
|
200 | (1) |
|
Studies with radioactive ligands |
|
|
200 | (1) |
|
NK-1 receptor binding sites |
|
|
200 | (1) |
|
NK-2 receptor binding sites |
|
|
201 | (1) |
|
NK-3 receptor binding sites |
|
|
201 | (1) |
|
In situ hybridization studies |
|
|
201 | (1) |
|
|
201 | (1) |
|
|
202 | (1) |
|
|
202 | (1) |
|
Immunocytochemical studies |
|
|
202 | (1) |
|
|
203 | (2) |
|
|
205 | (1) |
|
|
205 | (20) |
|
Confocal and ultrastructural studies |
|
|
225 | (3) |
|
|
228 | (1) |
|
|
228 | (1) |
|
Are tachykinins mostly involved in `volume' transmission? |
|
|
229 | (3) |
|
|
232 | (1) |
|
|
232 | (2) |
|
|
234 | (1) |
|
|
234 | (7) |
|
Brain Kallikrein-Kinin System: From Receptors to Neuronal Pathways and Physiological Functions |
|
|
|
|
|
|
|
|
|
|
|
|
241 | (1) |
|
The kallikrein--kinin system |
|
|
242 | (7) |
|
|
243 | (4) |
|
Signal transduction pathways |
|
|
247 | (1) |
|
|
247 | (2) |
|
Regional distribution of the kallikrein-kinin system in the central nervous system |
|
|
249 | (13) |
|
Kinin precursors (kininogens) |
|
|
249 | (1) |
|
Kinin synthesizing enzymes (kininogenases) |
|
|
249 | (2) |
|
Active molecules (kinins) |
|
|
251 | (6) |
|
Kinin degrading enzymes (kininases) |
|
|
257 | (4) |
|
|
261 | (1) |
|
On the physiological role for kinins in central cardiovascular regulation |
|
|
262 | (12) |
|
Mechanisms subserving the cardiovascular effects of kinins in the CNS |
|
|
262 | (4) |
|
Site of action for cardiovascular effects of kinins in the CNS |
|
|
266 | (5) |
|
Receptors mediating the cardiovascular effects of kinins in the CNS |
|
|
271 | (2) |
|
Endogenous kinins in central control of blood pressure |
|
|
273 | (1) |
|
On the physiological role for kinins in the spinal cord |
|
|
274 | (5) |
|
Other central effects of kinins |
|
|
279 | (4) |
|
Considerations and perspectives |
|
|
283 | (3) |
|
|
286 | (1) |
|
|
287 | (1) |
|
|
288 | (1) |
|
|
288 | (13) |
|
Calcitonin Gene-Related Peptide (CGRP), Amylin and Adrenomedullin: Anatomical Localization and Biological Functions in the Mammalian and Human Brains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discovery and genomic composition |
|
|
301 | (3) |
|
Structure of CGRP and structure--activity relationships |
|
|
304 | (1) |
|
|
305 | (1) |
|
|
306 | (1) |
|
Neuroanatomical localization |
|
|
307 | (28) |
|
CGRP mRNA containing neurons |
|
|
307 | (1) |
|
CGRP-like immunoreactivity in the brain |
|
|
308 | (1) |
|
CGRP-immunoreactive cell bodies |
|
|
308 | (6) |
|
CGRP-immunoreactive fibers |
|
|
314 | (1) |
|
|
314 | (2) |
|
Amylin-like immunoreactivity in the brain |
|
|
316 | (1) |
|
Adrenomedullin-like immunoreactivity in the brain |
|
|
317 | (1) |
|
Receptor distribution and characterization |
|
|
317 | (1) |
|
|
317 | (1) |
|
Telencephalic CGRP binding sites |
|
|
317 | (3) |
|
Diencephalic CGRP binding sites |
|
|
320 | (1) |
|
Mesencephalic CGRP binding sites |
|
|
321 | (1) |
|
Pontine CGRP binding sites |
|
|
322 | (1) |
|
Cerebellar CGRP binding sites |
|
|
323 | (1) |
|
Myelencephalic CGRP binding sites |
|
|
323 | (1) |
|
Spinal CGRP binding sites |
|
|
323 | (1) |
|
CGRP-like immunoreactivity and binding sites in the human brain |
|
|
323 | (2) |
|
|
325 | (2) |
|
|
327 | (4) |
|
|
331 | (1) |
|
Amylin binding sites in the brain |
|
|
332 | (1) |
|
|
332 | (1) |
|
Separate receptors for CGRP, amylin and ADM? |
|
|
333 | (2) |
|
|
335 | (18) |
|
Fiber pathways containing CGRP |
|
|
335 | (1) |
|
|
335 | (1) |
|
|
336 | (1) |
|
|
337 | (1) |
|
CGRP and learning behaviors |
|
|
337 | (1) |
|
CGRP and taste and feeding |
|
|
338 | (1) |
|
CGRP and autonomic functions |
|
|
339 | (1) |
|
CGRP-induced behavioral changes |
|
|
340 | (1) |
|
CGRP and motoneurons: development and functions |
|
|
341 | (2) |
|
|
343 | (2) |
|
|
345 | (1) |
|
CGRP effects in the cardiovascular system |
|
|
346 | (2) |
|
CGRP effects in the gastrointestinal tract |
|
|
348 | (1) |
|
Central and peripheral effects of amylin |
|
|
349 | (2) |
|
Central and peripheral effects of adrenomedullin |
|
|
351 | (2) |
|
Conclusion and perspectives |
|
|
353 | (1) |
|
|
353 | (3) |
|
|
356 | (1) |
|
|
356 | (19) |
|
Neuropeptide Y, Peptide YY and Pancreatic Polypeptide Receptor Proteins and mRNAs in Mammalian Brains |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
375 | (2) |
|
Biological effects of NPY and related peptides |
|
|
377 | (1) |
|
NPY, PYY and PP receptor subtypes |
|
|
378 | (4) |
|
The Y1 and Y2 receptor subtypes |
|
|
378 | (2) |
|
|
380 | (1) |
|
|
381 | (1) |
|
|
381 | (1) |
|
The `so-called' Y3 receptor subtype |
|
|
382 | (1) |
|
Other NPY receptor subtypes? |
|
|
382 | (1) |
|
Agonists and antagonists of the NPY family |
|
|
382 | (4) |
|
|
382 | (2) |
|
|
384 | (1) |
|
|
384 | (1) |
|
|
385 | (1) |
|
|
385 | (1) |
|
NPY receptors in the rat brain |
|
|
386 | (35) |
|
Characterization of NPY receptors in the rat brain |
|
|
386 | (3) |
|
|
389 | (4) |
|
Distribution of NPY receptor subtypes in rat brain |
|
|
393 | (3) |
|
|
396 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
396 | (1) |
|
Distribution of the Y2 receptor subtype |
|
|
396 | (1) |
|
Distribution of the Y4 receptor subtype |
|
|
396 | (5) |
|
Distribution of the Y5 receptor subtype |
|
|
401 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
401 | (1) |
|
|
402 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
402 | (1) |
|
Distribution of the Y2 receptor subtype |
|
|
402 | (8) |
|
Distribution of the Y4 receptor subtype |
|
|
410 | (1) |
|
Distribution of the Y5 receptor subtype |
|
|
410 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
411 | (1) |
|
|
411 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
411 | (1) |
|
Distribution of the Y2 receptor subtype |
|
|
412 | (1) |
|
Distribution of the Y4 receptor subtype |
|
|
412 | (1) |
|
Distribution of the Y5 receptor subtype |
|
|
412 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
413 | (1) |
|
|
413 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
413 | (1) |
|
Distribution of the Y2 receptor subtype |
|
|
413 | (1) |
|
Distribution of the Y4 receptor subtype |
|
|
414 | (1) |
|
Distribution of the Y5 receptor subtype |
|
|
414 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
414 | (1) |
|
|
414 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
414 | (4) |
|
Distribution of the Y2 receptor subtype |
|
|
418 | (1) |
|
Distribution of the Y4 receptor subtype |
|
|
418 | (1) |
|
Distribution of the Y5 receptor subtype |
|
|
418 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
418 | (1) |
|
|
419 | (1) |
|
Distribution of the Y1 receptor subtype |
|
|
419 | (2) |
|
Distribution of the Y2 receptor subtype |
|
|
421 | (1) |
|
Distribution of the Y4 receptor subtype |
|
|
421 | (1) |
|
Distribution of the Y5 receptor subtype |
|
|
421 | (1) |
|
Distribution and expression of the Y1, Y2, Y4 and Y5 receptor mRNA |
|
|
421 | (1) |
|
NPY receptor subtypes in other species |
|
|
421 | (16) |
|
Distribution of NPY receptor subtypes in the mouse brain |
|
|
423 | (1) |
|
Distribution of NPY receptor subtypes in the guinea-pig brain |
|
|
423 | (2) |
|
Distribution of NPY receptor subtypes in the marmoset monkey (Callitrix jacchus) brain |
|
|
425 | (6) |
|
Distribution of NPY receptor subtypes in the vervet monkey (Cercopithecus pygerythrus) brain |
|
|
431 | (1) |
|
Distribution of NPY-like immunoreactivity and NPY receptor subtypes in the human brain |
|
|
431 | (6) |
|
Interactions of NPY with various neuronal populations |
|
|
437 | (5) |
|
|
437 | (1) |
|
|
437 | (2) |
|
|
439 | (1) |
|
|
440 | (1) |
|
|
441 | (1) |
|
Physiological and pathophysiological implications of NPY and its receptors |
|
|
442 | (8) |
|
|
442 | (2) |
|
|
444 | (1) |
|
Learning behaviors and aging |
|
|
444 | (1) |
|
|
445 | (1) |
|
Thermoregulation, neuroendocrine regulation and circadian rhythms |
|
|
446 | (1) |
|
|
446 | (1) |
|
Neuroendocrine regulation |
|
|
446 | (1) |
|
|
447 | (1) |
|
|
447 | (1) |
|
Opioid withdrawal and alcoholism |
|
|
448 | (1) |
|
Cardiorespiratory function |
|
|
449 | (1) |
|
|
449 | (1) |
|
Non-neuronal effects of NPY-like peptides |
|
|
450 | (1) |
|
|
450 | (1) |
|
|
451 | (4) |
|
|
455 | (1) |
|
|
456 | (21) |
|
Multiple Brain Corticotropin-Releasing Factor Receptors and Binding Protein |
|
|
|
|
|
|
|
|
|
|
|
Introduction and historical perspectives |
|
|
477 | (1) |
|
|
477 | (2) |
|
Amino acid sequence and structure of CRF |
|
|
477 | (1) |
|
Amino acid sequence and structure of urocortin |
|
|
478 | (1) |
|
Organization of the CRF gene and protein precursor |
|
|
479 | (1) |
|
Organization of the urocortin gene and protein precursor |
|
|
479 | (1) |
|
Neuroanatomy of the CRF family of peptides |
|
|
479 | (3) |
|
Distribution of CRF in the central nervous system |
|
|
479 | (3) |
|
Distribution of urocortin in the central nervous system |
|
|
482 | (1) |
|
CRF receptors and binding protein |
|
|
482 | (23) |
|
Molecular biology/receptor structure |
|
|
482 | (1) |
|
|
482 | (1) |
|
|
483 | (2) |
|
CRF receptor splice variants |
|
|
485 | (1) |
|
|
485 | (1) |
|
Pharmacological characteristics |
|
|
486 | (1) |
|
Ligand binding profile of CRF1 receptors |
|
|
486 | (1) |
|
Ligand binding profile of CRF2 receptors |
|
|
486 | (1) |
|
Ligand binding profile of CRF-BP |
|
|
487 | (1) |
|
Guanine nucleotide characteristics of CRF receptors |
|
|
488 | (1) |
|
Second messenger characteristics of CRF receptors |
|
|
488 | (1) |
|
Localization of ligand-binding domains of CRF receptors: chimera and mutational studies |
|
|
489 | (1) |
|
Localization and function of CRF receptors and binding protein |
|
|
490 | (1) |
|
CRF receptor subtype(s) in brain and pituitary gland |
|
|
491 | (1) |
|
|
491 | (8) |
|
|
499 | (2) |
|
CRF2 receptor splice variants |
|
|
501 | (1) |
|
CRF-binding protein in brain and pituitary gland |
|
|
502 | (3) |
|
|
505 | (1) |
|
|
505 | (1) |
|
|
505 | (4) |
Subject Index |
|
509 | |